Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Nizar M. Tannir,David F. McDermott,Bernard Escudier,Hans J. Hammers,Osvaldo Rudy Aren,Elizabeth R. Plimack,Philippe Barthélémy,Victoria Neiman,Saby George,Camillo Porta,Thomas Powles,Frede Donskov,Marc-Oliver Grimm,Asim Amin,Scott S. Tykodi,Yoshihiko Tomita,Brian I. Rini,M. Brent McHenry,Shruti Shally Saggi,Robert J. Motzer

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

2020

609Background: N+I demonstrated superior OS and ORR v S in intention-to-treat (ITT) and intermediate/poor-risk (IP) pts with aRCC in CheckMate 214. Here, we report OS, response outcomes per indepen...

Keywords:

Oncology
Ipilimumab
Pathology
Nivolumab
Checkmate
Renal cell carcinoma
Internal medicine
Medicine
first line
Sunitinib
month follow up
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations